肿瘤细胞治疗研究
英文原题：Advances in CAR-T therapy for central nervous system tumors.
CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展；
CAR-T 细胞疗法用于中枢神经系统肿瘤已取得显著进展；然而，与其治疗急性淋巴细胞白血病和弥漫大B细胞淋巴瘤等血液系统恶性肿瘤中的成功不同，该疗法仍面临血脑屏障、免疫抑制性微环境和抗原异质性等挑战。本综述考察CAR-T 细胞疗法治疗胶质瘤、髓母细胞瘤及中枢神经系统淋巴造血系统肿瘤的研究进展，重点介绍临床前和临床研究中靶向EGFRvIII、HER2、B7H3、GD2和CD19等抗原的CAR-T细胞。本文综合当前研究结果，为未来中枢神经系统肿瘤CAR-T细胞治疗策略提供有价值的见解，并推动该疗法在这一领域的开发和应用。
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue to be encountered, unlike its success in hematological malignancies such as acute lymphoblastic leukemia and diffuse large B-cell lymphomas. This review examined the research progress of chimeric antigen receptor T-cell therapy in gliomas, medulloblastomas, and lymphohematopoietic tumors of the central nervous system, focusing on chimeric antigen receptor T-cells targeting antigens such as EGFRvIII, HER2, B7H3, GD2, and CD19 in preclinical and clinical studies. It synthesized current research findings to offer valuable insights for future chimeric antigen receptor T-cell therapeutic strategies for central nervous system tumors and advance the development and application of this therapeutic modality in this domain.
MEMBER ACCOUNT
登录成功会直接打开下一页。
